Dr. Ailawadhi on the Safety Profile of Lisaftoclax in CLL


In Partnership With:

Sikander Ailawadhi, MD, discusses the safety profile of lisaftoclax in chronic lymphocytic leukemia.

Sikander Ailawadhi, MD, consultant, Division of Hematology/Oncology, Department of Internal Medicine, professor of medicine, Division of Hematology/Oncology, Departments of Medicine and Cancer Biology, Mayo Clinic, discusses the safety profile of lisaftoclax in chronic lymphocytic leukemia (CLL).

During the 2021 ASCO Annual Meeting, findings from a first-in-human study of the novel BCL-2 inhibitor lisaftoclax were presented, demonstrating an 80% overall response rate in patients with relapsed/refractory CLL and small lymphocytic lymphoma.

Regarding safety, no dose-limiting toxicities were observed with up to 1,200 mg/day of lisaftoclax, says Ailawadhi. Any-grade adverse effects (AEs) were observed in 75% of patients and consisted of fatigue (n = 10; 27.8%), neutropenia (n = 8; 22.2%), diarrhea (n = 7; 19.4%), anemia (n = 6; 16.7%), constipation (n = 4; 11.1%), and nausea (n = 4; 11.1%), Ailawadhi explains. Grade 3 or higher AEs were rare and included neutropenia (n = 5; 13.9%), nausea (n = 2; 5.6%), and decreased platelet counts (n = 2; 5.6%).

Notably, no cases of laboratory or clinical tumor lysis syndrome were observed with lisaftoclax, Ailawadhi says. This suggests that lisaftoclax could offer patients a novel treatment approach that doesn’t require hospitalization or slow dose-escalation, concludes Ailawadhi.

Related Videos
Michael R. Cook, MD
Andre Goy, MD
Peter Schmid, MD, PhD
Seema A. Khan, MD
Roisin E. O'Cearbhaill, MD
Stephen J. Freedland, MD
Tapan M. Kadia, MD,
Sara M. Tolaney, MD, MPH
Javier Cortés, MD, PhD,
Stephanie L. Graff, MD